Table 2.
Baseline characteristics of included studies
| Author, yr | Patients, n | Age, yr | Male, % | DM, % | HTN, % | CKD, % | HF, % | CAD, % | Afib, % | LVEF, % | ACEi/ARB, % | BB, % | Diuretic, % | Cr, mg/dl | eGFR, ml/min per 1.73 m2 | Hgb, g/dl | WRF, % | Decongestion (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Breidhardt et al.,26 2017 | 1019 | 77.9 | 54.9 | 30.6 | 76.2 | 44 | 49.4 | 24.9 | N/A | 45 | 56.1 | 51.7 | 54 | N/A | N/A | N/A | 33.2 | 21.3 |
| Brisco et al.,32 2016 | 301 | 66.0 | 73.4 | 52.5 | 80.4 | N/A | 74.4 | N/A | N/A | 34.5 | 63.8 | 83.4 | 100 | 1.6 | 51.8 | 11.7 | 15.5 | 46.1 |
| Fudim et al.,22 2018 | 206 | N/A | 73.8 | 31.1 | N/A | N/A | 54.9 | 44.8 | N/A | 20 | 78.2 | 64.6 | 98.5 | N/A | N/A | N/A | 44.8 | 47.8 |
| Martins et al.,27 2018 | 618 | 79 | 41.9 | 36.2 | 60.7 | 22.5 | N/A | 20.5 | N/A | 43 | 65 | 32.4 | 66.7 | 1.4 | N/A | 12.2 | 49 | 43.2 |
| Metra et al.,20 2012 | 594 | 69.1 | 74 | 35 | 53 | 35 | 66 | 56 | 36 | 33.3 | 76 | 60 | 99 | 1.6 | 42.8 | 12.8 | 50.2 | 87.2 |
| Metra et al.,29 2018 | 1537 | 70 | 66.4 | 45.3 | 79.4 | N/A | 66.4 | 38.6 | 53.5 | 30.3 | N/A | N/A | N/A | 1.3 | 49 | 12.7 | 20.5 | 77.4 |
| Rao et al.,31 2019 | 188 | 67.5 | 70.5 | 62.0 | N/A | N/A | 73.3 | 60.6 | 51.5 | 32.5 | 51.0 | 73.5 | 88.0 | 1.99 | N/A | N/A | 26.4 | 41.1 |
| Salah et al.,25 2015 | 1232 | 74 | 60 | 32 | 50 | N/A | 74 | 49 | 43 | N/A | 66 | 57 | 95 | 1.52 | 56.3 | 12.57 | 10.9 | 56.8 |
| Skolski et al.,28 2019 | 266 | 67 | 70.7 | 36.8 | 56 | 38.7 | 72.9 | 51.5 | 48.5 | 35 | 65.8 | 69.2 | 7.9 | 1.2 | 54.3 | 13 | 14.3 | 71.8 |
| Stolfo et al.,24 2017 | 122 | 69.3 | 74 | 28 | N/A | 61 | N/A | 53 | 31 | 34.7 | N/A | N/A | N/A | 1.44 | 55.1 | 12.4 | 23 | 59.8 |
| Testani et al.,21 2011 | 386 | 56.4 | 74.1 | 31.9 | 46.6 | N/A | 50.3 | 50.3 | N/A | 19.5 | N/A | N/A | N/A | N/A | 56.9 | 12.5 | 20.5 | 50 |
| Wattad et al.,23 2015 | 762 | 77.1 | 49.7 | 45 | 87.7 | N/A | 46 | 66 | 47.1 | N/A | 71 | 66.1 | N/A | 1.3 | 51 | 11.7 | 27 | 66.8 |
| Wettersten et al.,30 2019 | 814 | 69 | 63 | 44 | 80.1 | 26 | N/A | 47 | N/A | N/A | 31.4 | 72 | 70.8 | 1.2 | 60 | 11.7 | 32.2 | 51.7 |
ACEi, angiotensin-converting enzyme inhibitor; Afib, atrial fibrillation; ARB, angiotensin II receptor blocker; BB, beta blocker; BUN, blood urea nitrogen; CAD, coronary artery disease; CKD, chronic kidney disease; Cr, creatinine; DM, diabetes; eGFR, estimated glomerular filtration rate; HF, heart failure; Hgb, hemoglobin; HTN, hypertension; LVEF, left ventricular ejection fraction; N/A, not available; NOS, Newcastle-Ottawa scale; WRF, worsening renal function.